source
- BioMarin halts development of BMN401 enzyme therapy after mixed Phase 3 resultsBioMarin announced it will stop work on BMN401, an enzyme replacement therapy aimed at treating ENPP1 deficiency, a rare genetic disorder. The decision follows a Phase 3 trial that produced mixed…
- Pfizer exec says China's biotech growth will decelerate as firms hit R&D frontierAndrew Baum of Pfizer told Endpoints News that China's rapid biotech progress is expected to slow as companies move into more advanced research and development. He explained that as Chinese firms…